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It is widely accepted that the essential role of TRAF6 in vivo is to
generate the Lys63-linked ubiquitin (K63-Ub) chains needed to
activate the “master” protein kinase TAK1. Here, we report that
TRAF6 E3 ligase activity contributes to but is not essential for the
IL-1–dependent formation of K63-Ub chains, TAK1 activation, or IL-8
production in human cells, because Pellino1 and Pellino2 generate the
K63-Ub chains required for signaling in cells expressing E3 ligase-
inactive TRAF6 mutants. The IL-1–induced formation of K63-Ub chains
and ubiquitylation of IRAK1, IRAK4, and MyD88 was abolished in
TRAF6/Pellino1/Pellino2 triple-knockout (KO) cells, but not in TRAF6
KO or Pellino1/2 double-KO cells. The reexpression of E3 ligase-
inactive TRAF6 mutants partially restored IL-1 signaling in TRAF6
KO cells, but not in TRAF6/Pellino1/Pellino2 triple-KO cells. Pellino1-
generated K63-Ub chains activated the TAK1 complex in vitro with
similar efficiently to TRAF6-generated K63-Ub chains. The early phase
of TLR signaling and the TLR-dependent secretion of IL-10 (controlled
by IRAKs 1 and 2) was only reducedmodestly in primarymacrophages
from knockin mice expressing the E3 ligase-inactive TRAF6[L74H]
mutant, but the late-phase production of IL-6, IL-12, and TNFα (con-
trolled only by the pseudokinase IRAK2) was abolished. RANKL-
induced signaling in macrophages and the differentiation of bone
marrow to osteoclasts was similar in TRAF6[L74H] and wild-type cells,
explainingwhy the bone structure and teeth of the TRAF6[L74H] mice
was normal, unlike TRAF6 KOmice. We identify two essential roles of
TRAF6 that are independent of its E3 ligase activity.
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TNF receptor-associated factor 6 (TRAF6) is essential for manybiological processes (1). These include the myeloid differen-
tiation primary response gene 88 (MyD88) signaling network of
the innate immune system, RANK ligand (RANKL)-dependent
signaling and osteoclast formation, lymph node organogenesis (2),
and the development of hair follicles, sweat glands, and sebaceous
glands (3). TRAF6 expression is also needed for CD40 signaling in
B cells (4), the maturation and development of dendritic cells (5),
and the regulation of T-cell function (6, 7).
In innate immunity, nearly all Toll-like receptors (TLRs), as
well as the receptors of the interleukin 1 (IL-1) family of cytokines,
initiate signaling by recruiting the adaptor protein MyD88. This is
followed by the interaction of IL-1-receptor (IL-R)-associated
kinase 4 (IRAK4) with MyD88 and then the interaction of other
IRAK family members with IRAK4, to form an oligomeric com-
plex, termed the Myddosome (8, 9). IRAK1 and IRAK2 can then
interact with TRAF6 (10, 11) and induce TRAF6 dimerization
(12), which triggers the activation of its E3 ligase activity (13).
TRAF6 catalyzes the formation of Lys63-linked ubiquitin
(K63-Ub) chains in vitro in the presence of Ubc13-Uev1a (also
called UBE2N-UBE2V1), an E2 conjugating enzyme that directs
the formation of this type of ubiquitin linkage (14, 15). Although
truncated forms of TRAF6 lacking the really interesting new
gene (RING) domain were reported to restore IL-1-signaling to
TRAF6 knockout (KO) mouse embryonic fibroblasts (MEFs)
many years ago (16), other laboratories reported subsequently that
the E3 ligase-inactive TRAF6[C70A] mutant could not (12, 17,
18). These reports led to widespread acceptance of the notion that
the E3 ligase activity of TRAF6 is essential for IL-1 signaling.
Moreover, TRAF6-generated K63-Ub oligomers were shown to
activate the protein kinase TAK1 (also called MAP3K7) in vitro
(14, 15). TAK1 has a critical role in the MyD88 signaling network,
because IL-1 signaling is abolished in TAK1 KO MEFs (19) or
in MEFs expressing catalytically inactive TAK1 (20). Cells express
two TAK1 complexes, each comprising the TAK1 catalytic subunit
and TAK1-binding protein 1 (TAB1) plus either TAB2 or the
related TAB3 (21). The specific interaction of K63-Ub chains with
the C-terminal Npl4 zinc finger (NZF) domains of TAB2 and
TAB3 (22, 23) is thought to induce a conformational change that
activates TAK1 (14, 15).
Two major roles of TAK1 are to activate the canonical IκB
kinase (IKK) complex, and mitogen-activated protein (MAP) ki-
nase kinases (MKKs) that switch on p38 MAP kinases and c-Jun
N-terminal kinases 1 and 2 (JNK1 and JNK2). The IKKβ com-
ponent of the IKK complex activates the transcription factors
NF-κB and IFN-regulatory factor 5 (IRF5) (24, 25), which are
essential for the transcription of genes encoding proinflammatory
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cytokines (26). IKKβ also activates the protein kinase Tpl2
(MAP3K8) by phosphorylating its p105/NFκB1 subunit (27, 28),
enabling Tpl2 to activate MEK1 and MEK2 (MAP or ERK
kinase), which in turn activate extracellular signal regulated kinase
1 (ERK1) and ERK2 (also called MAPK3 and MAPK1, re-
spectively). ERK1 and ERK2, together with p38α MAP kinase,
activate mitogen and stress-activated kinase 1 (MSK1) and MSK2,
which phosphorylate the cAMP response element-binding protein
(CREB) that controls the transcription of the antiinflammatory
cytokine IL-10 (29). Thus, TAK1 regulates the production of anti-
inflammatory as well as proinflammatory cytokines.
If TRAF6-generated K63-Ub chains are essential for MyD88
signaling, then the formation of K63-Ub chains should be re-
duced in TRAF6 KO cells, and signaling should be abolished
when WT TRAF6 is replaced by an E3 ligase-inactive mutant.
Here, we tested these predictions, which led to the interesting
and unexpected findings reported in this paper.
Results
The IL-1–Dependent Formation of K63-Ub Chains Is Unimpaired in
TRAF6 KO IL-1R* Cells. Our initial studies were performed in
HEK293 cells stably expressing low levels of the IL-1R (IL-1R*
cells) (Methods), which is a simple model system in which genes of
interest can be disrupted easily by using CRISPR/Cas9 gene-editing
technology. Similar to other mammalian cells, we found that IL-1β
signaling in IL-1R* cells required the expression of TRAF6 and
TAK1, as well the protein kinase activity of TAK1 (Fig. S1 A–C).
The KO of TRAF6 did not affect the expression of any component
of the MyD88 signaling pathway examined, apart from Pellino1, the
expression of which was increased, as discussed later.
To study the formation of IL-1β–dependent K63-Ub chains,
we captured them from the cell extracts using Halo-NZF2 beads
(30, 31) (Methods). Capture was quantitative because no further
K63-Ub chains were pulled down when the supernatant obtained
after the first Halo-NZF2 pull-down was subjected to a second
treatment with these beads (Fig. 1A). We found that K63-Ub
chains were present in cells not stimulated with IL-1β but in-
creased after stimulation for 10 min with IL-1β. Importantly, the
IL-1β–dependent formation of K63-Ub chains was similar in
TRAF6 KO and TRAF6-expressing IL-1R* cells (Fig. 1A), im-
plying that another IL-1–activated E3 ligase was generating K63-
Ub chains in the TRAF6 KO cells.
TRAF6 E3 Ligase Activity Is Not Essential for IL-1β Signaling in IL-1R*
Cells. The results shown in Fig. 1 led us to reinvestigate whether
TRAF6-generated K63-Ub chains were essential for IL-1 signal-
ing. The TRAF6[L74H] mutation prevents interaction with
E2 conjugating enzymes (12), whereas the TRAF6[C70A] mu-
tation disrupts the RING domain structure. As expected, both
mutants were devoid of E3 ligase activity in vitro, irrespective of
Fig. 1. The E3 ligase activity of human TRAF6 is not required for IL-1β signaling in IL-1R* cells. (A) WT or TRAF6 KO IL-1R* cells were stimulated for 10 min
with IL-1β, and K63-Ub chains were pulled down (PD) from the cell extracts on Halo-NZF2 beads. The supernatant was subjected to a second PD using fresh
Halo-NZF2 beads. The K63-Ub chains were released with SDS and detected by immunoblotting with a specific antibody. (B) The activity of WT TRAF6 (5.0 nM)
and the indicated TRAF6 mutants (50 nM) was assayed using FLAG-ubiquitin as in Methods. Reactions were terminated in SDS and Ub-chain formation
detected by immunoblotting with anti-FLAG (which also detected Ub-loaded UBE1). (C) UntaggedWT TRAF6, TRAF6[C70A], or TRAF6[L74H] were reexpressed
in TRAF6 KO IL-1R* cells under the control of a doxycycline-inducible promoter. After stimulation with IL-1β, cell extracts were denatured in SDS and
immunoblotted with antibodies recognizing all forms of TRAF6, TAK1, p38α MAPK, and GAPDH, and with antibodies recognizing the phosphorylated
(p) forms of TAK1, IKKα/β, p105, JNK1/2, and p38α/γ. (D) WT and TRAF6 KO IL-1R* cells were stimulated with IL-1β, and then RNA was extracted and IL-8 mRNA
measured by quantitative RT-PCR (q-RT-PCR). Results show fold increase in mRNA relative to the level in unstimulated cells and are presented as mean ± SEM
(n = 3). (E) As in C, except that the secretion of IL-8 was determined by ELISA. Results are presented as mean ± SEM (n = 3). (F and G) As in D and E, except that
WT TRAF6, TRAF6[C70A], or TRAF6[L74H] were reexpressed in TRAF6 KO IL-1R* cells. (H) As in C, except that TRAF6 KO IL-1R* cells were reconstituted with
FLAG-tagged WT TRAF6, TRAF6[120-522], or TRAF6[160-522]. *P < 0.05 (Methods).
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whether the E2 conjugating enzyme was Ubc13-Uev1A (Fig.
1B), UbcH5a (also called UBE2D1), or UbcH9 (also called
UBE2E3) (Fig. S2).
Next, we engineered the TRAF6 KO IL-1R* cells to reexpress
untagged E3 ligase-inactive TRAF6 mutants or WT TRAF6 un-
der a doxycycline-inducible promoter at levels that were similar to
the endogenous TRAF6 (Fig. 1C, Top). Interestingly, the reex-
pression of TRAF6[L74H] or TRAF6[C70A] partially restored
and the reexpression of WT TRAF6 fully restored IL-1β signaling
(Fig. 1C, panels 2–8 from Top) and IL-8 production (Fig. 1 D–G)
to TRAF6 KO cells.
IL-1β signaling could also be restored to TRAF6 KO IL-1R*
cells by the reexpression of TRAF6[120–522], which lacks the
N-terminal 119 residues of TRAF6 containing the RING domain
or by TRAF6[160–522], which lacks the RING domain plus the
first zinc finger (Fig. 1H). This experiment confirmed that the
E3 ligase activity of TRAF6 was not required for IL-1β signaling
in IL-1R* cells.
The TRAF6 E3 Ligase Is Dispensable for IL-1 and TLR Signaling in HaCaT
Cells.Because the results presented in Fig. 1 were unexpected, we
repeated them in the human keratinocyte HaCaT cell line in
which the IL-1R is not overexpressed and the level of the en-
dogenous IL-1R is undetectable by immunoblotting (Fig. S3).
Similar to IL-1R* cells, IL-1β–dependent signaling was abolished
in TRAF6 KO (Fig. 2A) or TAK1 KO HaCaT cells (Fig. 2B),
and IL-1-signaling could be partially restored to TRAF6 KO
HaCaT cells by reexpressing E3 ligase-inactive TRAF6 and fully
restored by reexpressing WT TRAF6 (Fig. 2C, top four panels).
The expression of TRAF6 is also essential for MyD88 signaling
induced by ligands that activate Toll-like receptors (TLRs). We
found that HaCaT cells responded to Pam2CSK4, an activator of the
TLR2/TLR6 heterodimer. Similar to IL-1β, Pam2CSK4-dependent
signaling was abolished in TRAF6 KO HaCaT cells, partially re-
stored by the reexpression of E3 ligase-inactive TRAF6mutants, and
fully restored by WT TRAF6 (Fig. 2D). Taken together, the results
presented in Figs. 1 and 2 establish that TRAF6, but not its E3 ligase
activity, is essential for MyD88 signaling in the two human cell
lines studied.
Pellino1 and Pellino2 Generate the K63-Ub Chains Required for MyD88
Signaling in IL-1R* Cells Expressing E3 Ligase-Inactive TRAF6. The
results presented in the preceding sections suggested that an-
other E3 ligase(s) was generating the K63-Ub chains required for
MyD88 signaling in cells expressing E3 ligase-inactive mutants of
TRAF6. Potential candidates to fulfill this role included mem-
bers of the Pellino family of RING domain E3 ligases (32), which
interact with IRAK1 (33, 34) and are converted from inactive to
active E3 ligases by IRAK1-catalyzed phosphorylation in vitro
(35, 36) and in cells (37). Like TRAF6, the Pellinos can also
combine with Ubc13-Uev1a to produce K63-Ub chains in vitro
(35, 36). Interestingly, the expression of Pellino1 (Fig. S1D) and
hence IL-1β–dependent Pellino1 E3 ligase activity (Fig. 3A) was
enhanced severalfold in TRAF6 KO cells (Fig. 3A). This appears
to be an effect on Pellino1 stability because Pellino1 mRNA
levels were only increased by 30% in TRAF6 KO cells, whereas
Pellino2 mRNA levels were unaltered (Fig. S1E). We also found
that Pellino1-generated K63-Ub chains were as effective as
TRAF6-generated K63-Ub chains in triggering the activation of
the TAB1–TAK1–TAB3 complex in vitro (Fig. 3B).
IL-1 stimulation induces the interaction of TRAF6 with Pro–
Xaa–Glu motifs present in the C-terminal domain of IRAK1
(10), whereas the Forkhead-associated (FHA) domain present in
Pellino isoforms interacts with phosphothreonine residues in IRAK1
(34). Consistent with the formation of a ternary complex between
these proteins, Pellino1 and Pellino2 were both detected along with
IRAK1 and TRAF6 when TRAF6 was immunoprecipitated from
the extracts of IL-1R* cells, provided that the cells had been
stimulated with IL-1β (Table S1). To investigate whether Pellino-
generated K63-Ub chains trigger IL-1β signaling in cells that ex-
press E3 ligase-inactive mutants of TRAF6, we generated triple-
KO IL-1R* cell lines lacking expression of TRAF6, Pellino1, and
Pellino2. IL-1β signaling was similar in Pellino1/2 double-KO cells
and WT IL-1R* cells, but abolished in either TRAF6 KO cells
or TRAF6/Pellino1/2 triple-KO cells (Fig. 3C). IL-1β signaling
could be partially restored by the reexpression of TRAF6[L74H]
or TRAF6[120-522] in TRAF6 KO IL-1R* cells (Fig. 3D, lanes
10–12 and 16–18), but not by the reexpression of these mutants in
the triple-KO cells (Fig. 3D, lanes 7–9 and 13–15). In contrast, the
reexpression of WT TRAF6 fully restored IL-1β signaling to either
Fig. 2. The E3 ligase activity of TRAF6 is not required for IL-1β or Pam2CSK4 signaling in HaCaT cells. (A and B) IL-1β signaling is abolished in TRAF6 KO (A) and
TAK1 KO (B) HaCaT cells. WT HaCaT cells and two independent clones of TRAF6 KO HaCaT cells (clones 22 and 44) or TAK1 KO HaCaT cells (clones 45 and 81)
were stimulated with IL-1β followed by immunoblotting with the antibodies indicated. (C) WT TRAF6 or the E3 ligase-inactive TRAF6[L74H] or TRAF6[C70A]
mutants were reexpressed in TRAF6 KO HaCaT cells (clone 44) under the control of a doxycycline-inducible promoter. Cells were stimulated with IL-1β and
immunoblotted with the antibodies indicated. (D) As in C, except that the HaCaT cells were stimulated with the TLR2/6 agonist Pam2CSK4.



























TRAF6 KO or TRAF6/Pellino1/2 triple-KO IL-1R* cells (Fig.
3D, lanes 3–6). Taken together, these results indicate that the
E3 ligase activities of TRAF6 and Pellino1/2 function redundantly
to generate the K63-Ub chains required for IL-1 signaling.
In contrast to TRAF6/Pellino1/2 triple-KO cells (Fig. 3D), the
reexpression of E3 ligase-inactive TRAF6 mutants partially re-
stored IL-1β signaling in either TRAF6/Pellino1 or TRAF6/
Pellino2 double-KO cells (Fig. S4 A and B), indicating that
Pellino1 or Pellino2 operate redundantly with one another to
generate the K63-Ub chains needed to initiate IL-1β signaling in
IL-1R* cells expressing E3 ligase-inactive mutants of TRAF6.
To study K63-Ub chain formation directly, we used Halo-
NZF2 beads to capture them from the cell extracts (Fig. 1A).
IL-1β stimulation induced the formation of K63-Ub chains in
TRAF6 KO cells, Pellino1/2 double-KO cells, and WT cells, but
not in TRAF6/Pellino1/2 triple-KO cells (Fig. 3E, Bottom, lanes
Fig. 3. The E3 ligase activities of TRAF6 and Pellinos 1 and 2 function redundantly in the IL-1 signaling network. (A) Immortalized WT and TRAF6 KO MEFs
were stimulated with IL-1α and Pellino1 immunoprecipitated from the cell extracts and assayed as described in Methods (Upper). The level of Pellino1 in the
immunoprecipitates and cell extracts (second and third panels) and GAPDH in the cell extracts (Bottom) were detected by immunoblotting. (B) Activation of
the TAB1–TAK1–TAB3 complex by TRAF6 or Pellino1-generated K63-Ub chains. The activation of TAK1 was studied in a coupled assay containing both its
substrate MKK6 and p38γMAP kinase, a substrate of MKK6 (Methods). (C) WT, TRAF6 KO, Pellino1/2 (Peli1/2) double KO, and two independent clones (B6, C5)
of TRAF6 /Pellino1/2 triple-KO IL-1R* cells were stimulated with IL-1β, and the cell extracts immunoblotted with the antibodies indicated. (D) Flag-tagged
WT TRAF6, TRAF6[L74H], or TRAF6[120-522] were reexpressed in TRAF6 KO or TRAF6/Peli1/2 triple-KO IL-1R* cells (clone B6). These cells (lanes 3–18) and
untransfected WT IL-1R* cells (lanes 1 and 2) were stimulated with IL-1β, and the extracts immunoblotted with the antibodies indicated. (E) As in C, except
that ubiquitylated forms of MyD88, p-IRAK4, IRAK1, and K63-Ub chains were captured on immobilized Halo-NZF2 beads and detected by immunoblotting
with specific antibodies. (F) Ubiquitylated IRAK1 was captured from the extracts of IL-1–stimulated (10 min) WT and TRAF6 KO IL-1R* cells on Halo-TUBEs.
Following incubation with λPPase with (+) or without (−) Otulin (Methods), IRAK1 was released with SDS and identified by immunoblotting. Due to the
enhanced formation of Ub-IRAK1 in TRAF6 KO cells, the blots in lanes 1–4 were exposed for 15 s and those in lanes 5–8 for 5 s. (G) Halo-NEMO beads were
used to capture M1-Ub chains from the extracts of WT IL-1R* cells or TRAF6 KO cells (Fig. 3G, lanes 1–6) or from TRAF6 KO cells reexpressing WT TRAF6 or the
indicated E3 ligase-inactive TRAF6 mutants. The M1-Ub chains were identified by immunoblotting with a specific antibody. IKKβ, which binds to NEMO, was
used as the loading control.
E3484 | www.pnas.org/cgi/doi/10.1073/pnas.1702367114 Strickson et al.
10–15). Some of the K63-Ub chains formed in response to IL-1
are attached covalently to the components of the Myddosome
(30). Importantly, the IL-1β–dependent formation of Ub-
IRAK1, Ub-IRAK4, or Ub-MyD88 was still robust in Pellino1/2
double-KO cells and TRAF6 KO IL-1R* cells, but abolished in
TRAF6/Pellino1/2 triple-KO IL-1R* cells (Fig. 3E). Similar results
were obtained with two different clones that were isolated in-
dependently. These findings confirm that TRAF6 and Pellino1 and
2 function redundantly in the IL-1β–dependent formation of K63-
Ub chains, K63-Ub-IRAK1, K63-Ub-IRAK4, and K63-Ub-MyD88.
MyD88 and IRAK4 form oligomeric complexes when they are
recruited to the IL-1 receptor, explaining why the Halo-NZF2 beads
capture the deubiquitylated as well as the ubiquitylated forms of
these proteins from the cell extracts (Fig. 3E).
The ubiquitin chains attached to IRAK1, IRAK4, and MyD88
are “hybrid” molecules containing both Met-linked ubiquitin
(M1-Ub) and K63-Ub linkages. The faster migration of the ubiq-
uitylated-IRAK1 in TRAF6 KO cells compared with WT cells
(Fig. 3E) is explained not by the generation of smaller K63-Ub
chains, but by a drastic reduction in the number of M1-Ub link-
ages. Thus, incubation with Otulin, a deubiquitylase that only hy-
drolyses M1-Ub chains (38), increased the electrophoretic mobility
of the Ub-IRAK1 formed in TRAF6-expressing cells (Fig. 3F,
lanes 1–4), whereas the mobility of the Ub-IRAK1 produced in
TRAF6 KO cells was only increased slightly by Otulin treatment
(Fig. 3F, lanes 5–8). The greatly reduced formation of M1-Ub
chains in TRAF6 KO cells was confirmed by immunoblotting
with an M1-Ub chain-specific antibody (Fig. 3G). The IL-1–
dependent formation of M1-Ub chains was restored by the reex-
pression of WT TRAF6 and partially restored by the reexpression
of E3 ligase-inactive mutants of TRAF6 (Fig. 3G).
MyD88 Signaling in Primary Macrophages from TRAF6[L74H] Mice.
Few TRAF6 KO mice survive for more than 2 wk after birth
(4), but the TRAF6[L74H] mice were still alive after 5 wk. However,
at this age, they were culled because they had developed inflam-
mation of the skin and other organs. A detailed analysis of the in-
flammatory phenotype will be presented in a separate publication.
To investigate the role of the TRAF6 E3 ligase in primary
macrophages, we generated a knockin mouse in which WT
TRAF6 was replaced by the E3 ligase-inactive TRAF6[L74H]
mutant (Fig. S5). The MyD88 signaling network in murine bone
marrow-derived macrophages can be divided into an early phase
up to 2 hr, which is characterized by robust but transient sig-
naling and the production of antiinflammatory molecules, such
as IL-10, and a late phase from 2 to 8 h, which is characterized by
weaker signaling, but a huge acceleration in the production of
proinflammatory cytokines (11). We found that early-phase sig-
naling (Fig. 4 A and B) and IL-10 secretion (Fig. 4 C and G)
induced by Pam3CSK4 (an activator of the TLR1/2 heterodimer)
or R848 (a TLR7 agonist) was only reduced modestly in com-
parison with WT macrophages. The TLR-dependent transcrip-
tion of il10 requires the MSK1/2-catalyzed phosphorylation of
the transcription factor CREB (see Introduction), which was
Fig. 4. MyD88-dependent signaling in macrophages from TRAF6[L74H] mice. (A) Fetal liver macrophages from WT, TRAF6[L74H], and TRAF6 KO mice were
stimulated with the TLR1/2 agonist, Pam3CSK4 (1 μg/mL). SDS-denatured cell extracts were separated by SDS/PAGE and immunoblotted with the indicated
antibodies. (B) As in A, except that the cells were stimulated with the TLR7 agonist, R848 (1 μg/mL). (C–F) As in A, except that, after stimulation with
Pam3CSK4, the concentrations of IL-10 (C), IL-6 (D), IL-12(p40) (E), and TNFα (F) in the culture medium were measured (mean ± SEM; n = 3). (G–J) As in C–F,
except that the macrophages were stimulated with R848. *P < 0.05 (Methods).



























slightly reduced in TRAF6[L74H] macrophages (Fig. 4 A and B),
consistent with the 50% reduction in IL-10 secretion observed in
these cells (Fig. 4 C and G). In contrast, the late-phase pro-
duction of TNFα, IL-6, and IL-12(p40) was reduced drastically in
macrophages from TRAF6[L74H] mice (Fig. 4 D–F and H–J).
Pam3CSK4 and R848 failed to elicit any signaling or cytokine
secretion in fetal liver macrophages from TRAF6 KO mice, as
expected (Fig. 4 A–J). A low basal level of IL-10 was detected
consistently in the culture medium of TRAF6 KO macrophages
incubated for 16 h before TLR stimulation. However, TLR li-
gation did not induce any increase in IL-10 secretion, as expected
(Fig. 4 C and G).
Similar to IL-1R* cells (Fig. S1D), the expression of many
components of the MyD88 signaling network was similar in the
fetal liver macrophages of TRAF6[L74H], TRAF6 KO, and WT
mice. However, the expression of Pellino1 was modestly en-
hanced in TRAF6 KO macrophages (Fig. S6).
IL-1 Signaling in MEFs from TRAF6[L74H] Knockin Mice. As reported
previously by others in immortalized TRAF6 KO MEFs (12, 17,
18) or TRAF6 KO monocytes (39), we found that IL-1 signaling
could be restored to immortalized TRAF6 KO MEFs by reex-
pressing the WT TRAF6 but not by the TRAF6[C70A] mutant,
whereas only trace IL-1 signaling was restored by the reex-
pression of TRAF6[L74H] (Fig. S7A). In contrast, IL-1α (Fig.
S7B) or IL-1β (Fig. S7C) signaling in primary MEFs from
TRAF6[L74H] knockin mice was clearly detectable, although
weaker than in WT MEFs. Why E3 ligase-inactive mutants of
TRAF6 are unable to restore significant IL-1 signaling to im-
mortalized TRAF6 KO MEFs, in contrast to human IL-1R* and
HaCaT cells, and in contrast to the MyD88-dependent signaling
that is clearly observed in primary macrophages and MEFs
from TRAF6[L74H] mice, is unclear. It is possible that the
TRAF6[C70A] mutant is unable to refold into a conformation ca-
pable of restoring IL-1 signaling in immortalized TRAF6 KOMEFs.
Generation and Phenotypic Analysis of TRAF6[L74H] Knockin Mice.
TRAF6 is essential for many other cell functions, and the most
striking phenotype of TRAF6 KO mice is independent of
MyD88 signaling. TRAF6 KO mice are 20–30% smaller than WT
mice, have deformed bones, and lack teeth (4). This phenotype is
caused by osteopetrosis, due to the failure of RANKL to induce the
production of osteoclasts (2, 4). RANKL, a TNF superfamily
member, signals via its receptor RANK, which interacts directly with
TRAF6 to initiate signaling (40, 41) by activating TAK1 (42, 43).
In contrast to TRAF6 KOmice, male or female TRAF6[L74H]
mice were of similar weight to their WT littermates (Fig. 5A) and
their teeth developed normally (Fig. 5B). The overall histological
structure of their long bones was similar to WT mice, showing no
evidence of osteopetrosis (Fig. 5C). Consistent with these obser-
vations, TRAF6[L74H] liver macrophages could be differentiated
into osteoclasts in the presence of RANKL and macrophage
colony-stimulating factor (M-CSF), but liver macrophages from
TRAF6 KO mice could not (Fig. 5D). RANKL-dependent sig-
naling was similar in macrophages from TRAF6[L74H] and WT
mice, although the activation of IKKα/β and their substrate
p105 was slightly reduced in TRAF6[L74H] macrophages (Fig.
5E). This was not due to a decrease in the expression of these
proteins (Fig. S6). In contrast to TRAF6[L74H] mice, RANKL
signaling was abolished in TRAF6 KO mice.
Other laboratories have reported that RANKL signaling cannot
be restored to TRAF6 KO monocytes by the reexpression of
TRAF6[C70A] (17, 39). This could be related to the problem dis-
cussed in the preceding section in refolding this E3 ligase-inactive
mutant in MEFs to a conformation that can support signaling.
Discussion
The notion that TRAF6-generated K63-Ub oligomers initiate
MyD88 signaling and other TRAF6-dependent processes has
underpinned the field of innate immunity for many years. How-
ever, in the present study, we found that two different E3 ligase-
inactive TRAF6 mutants (TRAF6[L74H] and TRAF6[C70A])
and even a TRAF6 mutant entirely lacking the RING domain,
partially restored MyD88 signaling in both TRAF6 KO IL-1R*
cells and HaCaT cells (Figs. 1 and 2). Further studies in IL-1R*
cells revealed that the E3 ligase function of TRAF6 was not es-
sential for IL-1 signaling because Pellino1 and Pellino2 were able to
generate the K63-Ub chains required to activate TAK1 complexes
Fig. 5. The phenotype and RANKL signaling in TRAF6[L74H] mice. (A) TRAF6[L74H] mice (black bars) are of similar size to their WT littermates (white bars).
The indicated number of mice were weighed at 22 d of age, and weights are presented as mean ± SEM. An unpaired Student t test indicated that the
differences were not significant. (B) The incisors of TRAF6[L74H] mice erupt similarly to WT littermate (33-d-old males). (C) H&E staining of bone (humerus)
sections from WT and TRAF6[L74H] male mice aged 31 and 33 d, respectively (scale bar, 0.5 mm). Note normal microscopic architecture of the epiphysis,
physeal growth plate cartilage, metaphysis, and diaphysis in the TRAF6[L74H] mouse. Similar results were obtained with bones from two further mice of each
genotype. (D) Fetal liver macrophages fromWT TRAF6 and TRAF6[L74H] mice, but not TRAF6 KO mice, differentiate into osteoclasts 6 d after stimulation with
100 ng/mL RANKL and M-CSF. Cells were fixed before staining for tartrate-resistant acid phosphatase and images were taken under bright-field microscopy at
4× magnification. (Scale bar, 0.2 mm.) (E) Fetal liver macrophages were stimulated with RANKL (100 ng/mL) and cell extract protein (20 μg) subjected to SDS/
PAGE and immunoblotting with the indicated antibodies.
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in cells expressing E3 ligase-inactive mutants of TRAF6. These
studies in model human cell lines led us to generate knockin mice
expressing the E3 ligase-inactive TRAF6[L74H] mutant and to
study MyD88 signaling in primary macrophages from these animals.
These experiments confirmed that the TRAF6 E3 ligase contributes
to, but is not required to trigger MyD88 signaling or IL-10 secretion
by TLR ligands that signal via MyD88 (Fig. 4).
Although the early phase (0–2 h) of MyD88-dependent sig-
naling and IL-10 secretion in TRAF6[L74H] macrophages was
relatively intact, the production of proinflammatory cytokines
(IL-6, IL-12, and TNFα), which takes place mainly during the
late phase (2–8 h), was abolished (Fig. 4). During the early
phase, IRAK1 and IRAK2 operate redundantly to induce sig-
naling and IL-10 production, but during the late-phase IRAK1
expression is greatly decreased (11), and so IRAK2 becomes rate
limiting. For this reason, the MyD88-dependent production of
IL-6, IL-12, and TNFα is abolished in bone marrow-derived
macrophages from IRAK2 KO mice (44) or in knockin mice
expressing an IRAK2 mutant that cannot interact with TRAF6
(11). Like IRAK1, IRAK2 can induce the dimerization of
TRAF6, which activates its E3 ligase activity (10, 12). However,
unlike IRAK1, IRAK2 is a catalytically inactive “pseudokinase”
(discussed in ref. 11) and unable to phosphorylate and activate
Pellino isoforms. This could explain why the E3 ligase activity of
TRAF6 is essential for late-phase signaling and proinflammatory
cytokine production. In contrast, the IRAK1-catalyzed activation
of Pellino isoforms may produce the K63-Ub chains required
for early-phase signaling and IL-10 production in macrophages
expressing the E3 ligase-inactive TRAF6[L74H] mutant. There-
fore, whether the TRAF6 E3 ligase is essential is likely to depend
on whether compensation by a Pellino isoform(s) or another
K63-Ub-generating E3 ligase(s) is possible. This may in turn
depend on the duration of the stimulus, as well as on the cell type
and cell function.
We found that RANKL-induced osteoclast formation and
RANKL signaling were similar in TRAF6[L74H] and WT mac-
rophages (Fig. 5). These finding are consistent with a report that
TRAF6 mutants lacking the RING domain restore RANKL-
dependent differentiation to multinuclear osteoclasts when reex-
pressed in TRAF6 KO splenocytes (16). They are also consistent
with the normal bone structure and teeth of the TRAF6[L74H]
mice (Fig. 5). These findings demonstrate that the E3 ligase ac-
tivity of TRAF6 is not required for RANKL signaling.
It will clearly be interesting to further exploit the TRAF6[L74H]
mouse to investigate whether other essential roles of TRAF6 (see
Introduction) require its E3 ligase activity and, if not, whether
Pellino isoforms generate the K63-Ub chains required in these
systems (Fig. 3). These studies will also require the TRAF6[L74H]
mouse to be crossed to mice expressing E3 ligase-inactive mutants
of Pellino1 and Pellino2, to generate triple-knockin mice deficient
in all three E3 ligase activities.
An important outcome of this study is that it has identified two
essential roles of TRAF6 in the MyD88 signaling network that are
independent of its E3 ligase activity. First, although Pellino1 and
Pellino2 generate the K63-Ub chains required for MyD88 signaling
in cells expressing E3 ligase-inactive TRAF6 mutants, no signaling
occurs in TRAF6 KO cells despite the unimpaired formation of
K63-Ub chains. These findings imply that TRAF6, but not its
E3 ligase activity, is required to couple K63-Ub chain formation to
the activation of TAK1. Second, the IL-1–dependent formation of
M1-Ub chains, catalyzed by the linear ubiquitin assembly complex
(LUBAC), is greatly reduced in TRAF6 KO cells, but can be par-
tially restored by reexpressing E3 ligase-inactive mutants of TRAF6.
The M1-Ub chains are not required for the IL-1–dependent TAK1-
catalyzed activation of MAP kinases, but for the TAK1-catalyzed
activation of the canonical IKK complex (45). Because the in-
trinsic catalytic activity of LUBAC is not altered by IL-1 stimulation
(30) and the expression of the components of LUBAC (HOIP,
HOIL-1, and Sharpin; Fig. S1D) is unimpaired in TRAF6 KO
cells, these observations suggest that TRAF6 could have a
critical role in recruiting LUBAC to the Myddosome. Precisely
how TRAF6 achieves these two essential “scaffolding” roles is
an interesting problem for future research.
Methods
Phosphospecific Antibodies Used to Monitor Activation of the MyD88 Signaling
Pathway. All antibodies were from Cell Signaling Technologies, unless
stated otherwise.
The activation of protein kinases in the pathway was monitored with
phosphospecific antibodies that recognize phosphorylation sites in their activa-
tion loops, which are known to be required for activation. These were TAK1
phosphorylated at Thr187 (#4536), IKKα phosphorylated at Ser176 and Ser180
(#2697), IKKβ phosphorylated at Ser177 and Ser181 (#2697); p38α and p38γ
MAP kinases phosphorylated at their Thr–Gly–Tyr motifs (#9211), ERK1 and
ERK2 phosphorylated at their Thr–Glu–Tyr motifs (#9101), MKK6 phosphorylated
at Ser207 (#12280), and JNK1 and JNK2 phosphorylated at their Thr–Pro–Tyr
motifs (#4668). The activation of several protein kinases was also monitored
by the phosphorylation of established substrates. The protein p105/NF-
κB1 phosphorylated at Ser933 (#4806) is a physiological substrate of IKKβ (27,
28), whereas MSK1 is phosphorylated at Thr581 (#9595) by p38α MAP kinase,
ERK1, and ERK2 in cells (46), and CREB is phosphorylated at Ser133 (#9198) by
MSK1 in cells (29).
Generation of IL-1R* Cells. HEK293 cells expressing FLAG-Cas9 under an in-
ducible promoter were provided by Yosua Kristariyanto and John Rouse [MRC
Protein Phosphorylation andUbiquitylation Unit (MRC-PPU), Dundee, Scotland,
UK] using the Flp-In T-Rex system (Invitrogen) (47). Retroviral particles con-
taining the IL-1R with a neomycin-resistance gene (DU46481) were generated
using a Murine Moloney Leukemia virus-based system prepared with the VSVG
envelope protein, according to the manufacturer’s instructions (Clontech). The
retroviral particles were incubated for 24 h with HEK293 FLAG-Cas9 cells with
2.0 μg/mL protamine sulfate (Sigma). Cells were selected by exposure to media
containing 1.0 mg/mL G418 for 1–2 wk.
The IL-1 receptor is overexpressed in IL-1R* cells, although at far lower
levels than in another widely used IL-1R–expressing cell line (Fig. S3) (48).
Generation of IL-1R* Cells Lacking Expression of TRAF6. The guide RNAs
(gRNAs) used to target the genes encoding TRAF6 are summarized in Table
S2. The gRNA plasmids targeting TRAF6 were pooled and 10 μg was used to
transfect IL-1R* cells for 8 h using the GeneJuice transfection reagent (Merck
Millipore). Doxycycline was then added to the cells to a final concentration
of 1.0 μg/mL, and a further 18 h later the cells were again transfected with
the same amounts of gRNA plasmids. After 48 h, cells were single-cell plated
into 96-well plates and left until colonies began to form (2–3 wk). The mu-
tation efficiency was analyzed by immunoblotting of the cell extracts.
Generation of Other KO IL-1R* and HaCaT Cell Lines. These cells were produced
by CRISPR/Cas9 technology using an improved procedure. One pair of gRNAs
was generated to target TRAF6, TAK1, IRAK1, Pellino1, or Pellino2. The
antisense gRNA was introduced to the vector encoding the Cas9[D10A]
mutant, which only cleaves one strand of the DNA molecule complementary
to the gRNA. In contrast, the sense gRNA was inserted into a plasmid con-
taining a puromycin resistance gene. Each gRNA plasmid (1.0 μg) was mixed
with 1.0 mL of serum-free DMEM and 0.02 mL of polyethylenimine (1.0 mg/mL)
(Fugene HD for HaCaT cells), and after incubation for 20 min at 20 °C,
the solution was added to the cells dropwise for transfection. After 24 and
48 h, the medium was replaced with fresh medium containing 2.0 μg/mL
puromycin. The cells were then single-cell plated into 96-well plates and left
until colonies began to form (2–3 wk). The mutational efficiency was ana-
lyzed by immunoblotting of the cell extracts for the relevant proteins.
Double-KO IL-1R* cells lacking expression of both TRAF6 and Pellino1 were
generated by targeting TRAF6-null IL-1R* cells with gRNAs specific for Pel-
lino1. Triple-KO IL-1R* cells lacking expression of TRAF6, Pellino1, and
Pellino2 were generated by targeting the TRAF6/Pellino1 double-KO cells
with gRNAs specific for Pellino2. The TRAF6/Pellino2 double-KO cells were
generated by targeting the TRAF6 KO cells with gRNA specific for Pellino2.
The Pellino1/Pellino2 double-KO cell lines were created in a similar fashion
by targeting Pellino1 KO cells with gRNA specific to Pellino2. Due to the lack of an
antibody that recognizes Pellino2, individual clones were screened for the absence
of Pellino2 by PCR amplifying and sequencing a 342-bp region of genomic DNA
containing the CRISPR target site (forward primer, ATTTGTTGCCGGCTCTGACT;
reverse primer, AGGGACCCCAGGACTCAC), allowing the visualization of indels.



























Reexpression of TRAF6 in TRAF6 KO IL-1R* Cells Using the Flp-In System. TRAF6
KO IL-1R* cells were cotransfected using GeneJuice (Millipore) with 9 μg of
POG44 recombinase (Invitrogen), and 1 μg of pcDNA5 FRT/TO vector containing
WT human TRAF6 or TRAF6 mutants containing a puromycin-resistance gene
(DU46785, DU46824, and DU46823). Forty-eight hours after transfection, cells
were selected with 2.0 μg/mL puromycin. To induce TRAF6 expression at levels
equivalent to the endogenous protein, reconstituted cells were incubated for
16 h with 0.03 ng/mL doxycycline for WT and TRAF6[L74H] and 0.3 ng/mL
for TRAF6[C70A].
Reexpression of TRAF6 and TAK1 in IL-1R* Cells, HaCaTs, and MEFs. Cells stably
reexpressing TRAF6 or TAK1 were generated by retroviral transduction as
described (45). Viruses encoding the gene of interest and the Tet-On protein
were harvested 48 h after transfection, diluted fourfold with fresh medium, and
incubated with the cells for 24 h in the presence of 2.0 μg/mL protamine sulfate
(Sigma). Fresh medium containing 1 mg/mL G418 (Tet-On) and 1 μg/mL puro-
mycin (gene of interest) was added to select the transduced cells. To induce
gene expression, cells were cultured for 16 h with 0.1–1.0 μg/mL doxycycline.
DNA encoding a TAK1 splice variant lacking DNA encoding amino acid residues
414–430 of the full-length protein were reexpressed in TAK1 KO IL-1R* cells (45).
Mouse TRAF6 and the mouse TRAF6[C70A] and TRAF6[L74H] (DU51028,
DU51041, and DU51027) mutants were reexpressed in TRAF6 KO MEFs.
Human TRAF6, TRAF6[C70A], and TRAF6[L74H] (DU51583, DU51585,
DU51584) were reexpressed in HaCaT cells.
Human FLAG-tagged TRAF6, TRAF6[L74H], TRAF6[120-522], and TRAF6
[160-522] (DU32495, DU46743, DU51445, and DU51447) were reexpressed
in IL-1R* cells. The vectors were expressed constitutively and did not require
cotransfection of Tet-On or doxycycline induction.
Generation of TRAF6 Knockin Mice and Maintenance of Mouse Lines. WT C57/
BL6micewere obtained from Charles River Labs, and knockin mice carrying the
Leu74His mutation in TRAF6 were made by TaconicArtemis using conventional
methods. Targeting vectors (Fig. S5) were constructed by recombinase-
mediated cloning to generate the desired mutations. They were then used
to target Art B6.3.5 (C57BL/6 NTac) ES cells. Positive colonies were identified by
Southern blotting and the presence of the point mutation confirmed by PCR
and sequencing of the appropriate genomic region. Correctly targeted ES cells
were used to generate chimeric mice via blastocyst injection. To remove the
neomycin and puromycin resistance selectable markers, mice were crossed to a
constitutive flp transgenic line (on a C57BL/6 background). Once deletion had
occurred, the TRAF6 allele was crossed away from the flp transgene. Routine
genotyping was carried out by PCR of ear biopsies. The sequences of the
primers used for TRAF6 were AATAGAAATCACCAGACTGGGC and CACA-
CAACAGTCAATGTTTACTAGG, which resulted in a band of 283 bp for a WT
allele and 357 bp for a knockin allele. Heterozygous TRAF6 KO mice were
provided by Tak Mak. Mice were maintained on a C57BL/6 background and
provided with free access to food and water. Animals were kept in ventilated
cages under specific-pathogen–free conditions in accordance with UK and
European Union regulations. Experiments were carried out subject to approval
by the University of Dundee ethical review board under a UK Home Office
project license.
Activation of the TAK1 Complex in Vitro. The purified TAB1–TAK1–TAB3 complex
(1.0 nM) was activated by incubation for 1 h at 30 °C with 0.2 μM UBE1, 1.0 μM
Ubc13-Uev1a, 12.5 μM ubiquitin, and either 0.4 μM TRAF6 or 0.4 μM Pellino1 in
50 mM Tris/HCl, pH 7.5, 2.0 mMATP, and 5 mMMgCl2 in a total reaction volume
of 0.03 mL. MKK6 (0.1 μM) and p38γ MAP kinase (0.5 μM) were also included.
Reactions were terminated by the addition of 5% (wt/vol) SDS and the activation
of TAK1 measured by immunoblotting with the antibody recognizing TAK1 at
Thr187 and by the phosphorylation of its substrate MAP kinase kinase 6 (MKK6)
at Ser207. The activation of MKK6 was also assessed with an antibody recog-
nizing the phosphorylated Thr–Gly–Tyr sequence in the activation loop of its
substrate p38γ MAP kinase. The expression of TAK1 and MKK6 was checked by
immunoblotting and the expression of p38γ MAP kinase by staining for protein
with Ponceau S. The formation of K63-Ub chains was examined by immuno-
blotting with a specific antibody.
IL-1 Preparations. Human IL-1β (DU8685) (30) and mouse IL-1α (DU46302) were
expressed in E. coli and purified by the PPT of the MRC-PPU. IL-1α was expressed
as a GST-fusion protein separated by a PreScission protease cleavage site and
purified on glutathione-Sepharose (GE Healthcare). GST-IL-1α was cleaved with
PreScission protease to release IL-1α [115–270] and purified by gel filtration on
Superdex G200. Endotoxin-free human IL-1α (200-01A), human IL-1β (200-01B)
and murine IL-1β (211-11B) were all purchased from Peprotech. The commer-
cial preparations of IL-1 were used to confirm that human IL-1α− and IL-β−
dependent signaling were similar in human IL-1R* cells (Fig. S8A) and to establish
that the commercial human IL-1β preparation induced signaling similarly to IL-1β
produced in the MRC-PPU (Fig. S8B). The mouse IL-1α produced in the MRC-PPU
and mouse IL-1β from Peprotech (211-11B) stimulated the MyD88 pathway
similarly in primary MEFs (Fig. S7 B and C).
Reproducibility and Statistical Analysis. All of the experiments reported in this
paperwere repeated at least three times with similar results. Statistical analyses
were performed with GraphPad Prism Software, and quantitative data in
graphs and bar charts are presented as the arithmetic mean ± SEM. Statistical
significance of differences between experimental groups was assessed in all
graphs and bar charts, using the two-way ANOVA with Bonferroni posttest,
unless indicated otherwise. Differences in means were considered significant if
P < 0.05 and indicated with an asterisk (*). Statistical differences that are not
significant are not highlighted by asterisks in the figures.
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